{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:37:27Z","timestamp":1740141447120,"version":"3.37.3"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Hospices Civils of Lyon"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Since June 2021 in France, patients with haemophilia A with anti-factor VIII inhibitors and patients with severe haemophilia A without anti-factor VIII inhibitors have the choice between the community and the hospital pharmacy for dispensing emicizumab (Hemlibra\u00ae). This study aims to investigate patient-centred access to treatment by evaluating and comparing the dimensions of the Penchansky and Thomas model, between community and hospital pharmacies. The evaluation of access to treatment was based on the dimensions of the Penchansky and Thomas model: accessibility, availability, acceptability, accommodation and affordability. These were assessed using appropriate and specific indicators in the study context and calculated for patients choosing community pharmacy or hospital pharmacy for emicizumab dispensing. Geographical data collected as part of the national \u2018PASO DOBLE DEMI\u2019 study were used for this analysis. The findings reveal that dispensing emicizumab in community pharmacies improves accessibility by significantly reducing travel time. The availability of healthcare services is also improved due to the territorial coverage of community pharmacies. The extended opening hours and low waiting time also contribute to better access to emicizumab in community pharmacies. The dimension of acceptability must be improved, and further investigations are needed to address the affordability dimension. Several months after emicizumab became available in French community pharmacies, access to treatment has significantly improved, reducing the burden of this rare chronic disease for patients and their careers. These results suggest that this innovative model could be extended to other medicines and even other therapeutic areas.<\/jats:p>","DOI":"10.1093\/eurpub\/ckae131","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T01:38:25Z","timestamp":1724981905000},"page":"866-871","source":"Crossref","is-referenced-by-count":0,"title":["Comparative evaluation of access to emicizumab (Hemlibra\u00ae) for people with haemophilia A in community and hospital pharmacies in France"],"prefix":"10.1093","volume":"34","author":[{"given":"Morgane","family":"Cabon","sequence":"first","affiliation":[{"name":"Haemophilia Treatment Centre and French Reference Centre on Haemophilia, Louis Pradel Hospital, Hospices Civils de Lyon , Bron,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Chamouard","sequence":"additional","affiliation":[{"name":"Haemophilia Treatment Centre and French Reference Centre on Haemophilia, Louis Pradel Hospital, Hospices Civils de Lyon , Bron,","place":["France"]},{"name":"Pharmaceutical Unit, Louis Pradel Hospital, Hospices Civils de Lyon , Bron,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Freyssenge","sequence":"additional","affiliation":[{"name":"Research on Healthcare Performance RESHAPE, INSERM U1290, University Claude Bernard Lyon 1 , Lyon,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2647-658X","authenticated-orcid":false,"given":"Laurie","family":"Fraticelli","sequence":"additional","affiliation":[{"name":"Laboratory P2S (Health Systemic Process), UR 4129, Faculty of Medicine Laennec, University Claude Bernard Lyon 1 , Lyon,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"2024092717500265700_ckae131-B1","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J Thromb Haemost"},{"key":"2024092717500265700_ckae131-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"World federation of hemophilia guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"year":"2023","author":"The French National Authority for Health (Haute Autorit\u00e9 de Sant\u00e9 - HAS)","key":"2024092717500265700_ckae131-B3"},{"key":"2024092717500265700_ckae131-B4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.japh.2019.07.006","article-title":"Access to treatment among persons with hemophilia: a spatial analysis assessment in the Rhone-Alpes region, France","volume":"59","author":"Leroy","year":"2019","journal-title":"J Am Pharm Assoc"},{"key":"2024092717500265700_ckae131-B5","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1111\/jcpt.13718","article-title":"PHAREO study: perceived and observed accessibility to therapeutic drugs used for treating patients with inherited bleeding disorders","volume":"47","author":"Chamouard","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"2024092717500265700_ckae131-B6","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/hae.14857","article-title":"Evaluation of the care pathway in the context of the dispensing of emicizumab (Hemlibra) in community and hospital pharmacies in France: a patient satisfaction survey","volume":"29","author":"Chamouard","year":"2023","journal-title":"Haemophilia"},{"key":"2024092717500265700_ckae131-B7","doi-asserted-by":"crossref","first-page":"e43091","DOI":"10.2196\/43091","article-title":"Evaluation of the care pathway in the context of the dispensing of emicizumab (Hemlibra) in community pharmacies in France: protocol for a cross-sectional study based on the Kirkpatrick model","volume":"12","author":"Fraticelli","year":"2023","journal-title":"JMIR Res Protoc"},{"key":"2024092717500265700_ckae131-B8","doi-asserted-by":"crossref","first-page":"e54656","DOI":"10.2196\/54656","article-title":"Evaluation of an e-learning program for community pharmacists for dispensing emicizumab (Hemlibra) in France: nationwide cross-sectional study","volume":"8","author":"Chamouard","year":"2024","journal-title":"JMIR Form Res"},{"key":"2024092717500265700_ckae131-B9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-9276-12-18","article-title":"Patient-centred access to health care: conceptualising access at the interface of health systems and populations","volume":"12","author":"Levesque","year":"2013","journal-title":"Int J Equity Health"},{"key":"2024092717500265700_ckae131-B10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00005650-198102000-00001","article-title":"The concept of access: definition and relationship to consumer satisfaction","volume":"19","author":"Penchansky","year":"1981","journal-title":"Medical Care"},{"key":"2024092717500265700_ckae131-B11","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1111\/1475-6773.12171","article-title":"Access to care: remembering old lessons","volume":"37","author":"McLaughlin","year":"2002","journal-title":"Health Serv Res"},{"key":"2024092717500265700_ckae131-B12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2516.2010.02280.x","article-title":"Confronting the psychological burden of haemophilia","volume":"17","author":"Coppola","year":"2011","journal-title":"Haemophilia"},{"year":"2018","author":"The French Ministry of Health and Solidarity (Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9)","key":"2024092717500265700_ckae131-B13"},{"key":"2024092717500265700_ckae131-B14","doi-asserted-by":"crossref","first-page":"S346","DOI":"10.1016\/j.amepre.2011.09.003","article-title":"Self-reported barriers to hemophilia care in people with factor VIII deficiency","volume":"41","author":"Zhou","year":"2011","journal-title":"Am J Prev Med"},{"key":"2024092717500265700_ckae131-B15","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.jval.2022.03.004","article-title":"Real-world impact of transferring the dispensing of hospital-only medicines to community pharmacies during the COVID-19 pandemic","volume":"25","author":"Murteira","year":"2022","journal-title":"Value Health"},{"key":"2024092717500265700_ckae131-B16","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3390\/pharmacy8030140","article-title":"The role of hospital and community pharmacists in the management of COVID-19: towards an expanded definition of the roles, responsibilities, and duties of the pharmacist","volume":"8","author":"Bragazzi","year":"2020","journal-title":"Pharmacy (Basel)"},{"key":"2024092717500265700_ckae131-B17"},{"year":"2023","author":"The French Chamber of Pharmacists (Ordre National des Pharmaciens)","key":"2024092717500265700_ckae131-B18"},{"key":"2024092717500265700_ckae131-B19","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1186\/s12889-015-2173-8","article-title":"Availability and acceptability of HIV counselling and testing services. A qualitative study comparing clients\u2019 experiences of accessing HIV testing at public sector primary health care facilities or non-governmental mobile services in Cape Town, South Africa","volume":"15","author":"Meehan","year":"2015","journal-title":"BMC Public Health"},{"key":"2024092717500265700_ckae131-B20","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.japh.2022.12.016","article-title":"Influence of patient-pharmacist relationship on willingness to accept pharmacist-provided services","volume":"63","author":"Adekunle","year":"2023","journal-title":"J Am Pharm Assoc"},{"key":"2024092717500265700_ckae131-B21","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/hex.12401","article-title":"Utilization of community pharmacy space to enhance privacy: a qualitative study","volume":"19","author":"Hattingh","year":"2016","journal-title":"Health Expect"},{"key":"2024092717500265700_ckae131-B22","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1475-6773.2011.01308.x","article-title":"Nonfinancial barriers and access to care for U.S. adults","volume":"47","author":"Kullgren","year":"2012","journal-title":"Health Serv Res"},{"key":"2024092717500265700_ckae131-B23","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1111\/hae.12545","article-title":"Haemophilia experiences, results and opportunities (HERO) study: treatment-related characteristics of the population","volume":"21","author":"Nugent","year":"2015","journal-title":"Haemophilia"},{"key":"2024092717500265700_ckae131-B24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/hae.14082","article-title":"The societal burden of haemophilia A. III\u2014The potential impact of emicizumab on costs of haemophilia A in Australia","volume":"26","author":"Brown","year":"2020","journal-title":"Haemophilia"},{"key":"2024092717500265700_ckae131-B25","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s40273-023-01308-0","article-title":"Are we capturing the socioeconomic burden of rare genetic disease? A scoping review of economic evaluations and cost-of-illness studies","volume":"41","author":"Marshall","year":"2023","journal-title":"PharmacoEconomics"}],"container-title":["European Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurpub\/article-pdf\/34\/5\/866\/59380265\/ckae131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurpub\/article-pdf\/34\/5\/866\/59380265\/ckae131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T17:50:20Z","timestamp":1727459420000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurpub\/article\/34\/5\/866\/7745436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,8,29]]},"published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurpub\/ckae131","relation":{},"ISSN":["1101-1262","1464-360X"],"issn-type":[{"type":"print","value":"1101-1262"},{"type":"electronic","value":"1464-360X"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,8,29]]}}}